Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Status:
Completed
Trial end date:
2018-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular
events and other serious outcomes in persons with type 2 diabetes, when added to their
anti-hyperglycemic regimen.